Sleep-related symptoms and sleep-disordered breathing in adult Pompe disease

European Journal of Neurology

Volumn 22, Issue 2, 2015, Pages 369-376

  Boentert, M ^a   Karabul, N ^b   Wenninger, S ^c   Stubbe Drager B ^a   Mengel, E ^b   Schoser, B ^c   Young, P ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Home ventilation; Hypoventilation; Pompe disease; Respiratory muscle weakness; Sleep quality

Indexed keywords

ADULT; AGED; ARTICLE; ASSISTED VENTILATION; BREATHING MUSCLE; CAPNOMETRY; COMORBIDITY; DAYTIME SOMNOLENCE; DYSPNEA; ENZYME REPLACEMENT; FATIGUE; FEMALE; FORCED VITAL CAPACITY; GLYCOGEN STORAGE DISEASE TYPE 2; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MUSCLE WEAKNESS; OXYGEN DESATURATION; PITTSBURGH SLEEP QUALITY INDEX; POLYSOMNOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; SLEEP DISORDERED BREATHING; SLEEP QUALITY; VENTILATED PATIENT; ADOLESCENT; COMPLICATION; MIDDLE AGED; PATHOPHYSIOLOGY; SLEEP APNEA SYNDROMES; SLEEP DISORDERS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FATIGUE; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MALE; MIDDLE AGED; RESPIRATORY MUSCLES; SLEEP APNEA SYNDROMES; SLEEP DISORDERS; YOUNG ADULT;

EID: 84920628333     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12582     Document Type: Article

References (27)

1. Bembi B, Cerini E, Danesino C, et al. Diagnosis of glycogenosis type II. Neurology 2008; 71(23 Suppl. 2): S4-S11.
2. Fukuda T, Roberts A, Ahearn M, et al. Autophagy and lysosomes in Pompe disease. Autophagy 2006; 2: 318-320.
3. Raben N, Roberts A, Plotz PH. Role of autophagy in the pathogenesis of Pompe disease. Acta Myol 2007; 26: 45-48.
4. Angelini C, Semplicini C. Enzyme replacement therapy for Pompe disease. Curr Neurol Neurosci Rep 2012; 12: 70-75.
5. Gungor D, de Vries JM, Hop WC, et al. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis 2011; 6: 34.
6. Mellies U, Lofaso F. Pompe disease: a neuromuscular disease with respiratory muscle involvement. Respir Med 2009; 103: 477-484.
7. van der Beek NA, Hagemans ML, van der Ploeg AT, et al. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. Acta Neurol Belg 2006; 106: 82-86.
8. Schuller A, Wenninger S, Strigl-Pill N, et al. Toward deconstructing the phenotype of late-onset Pompe disease. Am J Med Genet C Semin Med Genet 2012; 160: 80-88.
9. Müller-Felber W, Horvath R, Gempel K, et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 2007; 17: 698-706.
10. Hagemans ML, Winkel LP, Hop WC, et al. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 2005; 64: 2139-2141.
11. Hagemans ML, van Schie SP, Janssens AC, et al. Fatigue: an important feature of late-onset Pompe disease. J Neurol 2007; 254: 941-945.
12. de Vries JM, Hagemans ML, Bussmann JB, et al. Fatigue in neuromuscular disorders: focus on Guillain-Barre syndrome and Pompe disease. Cell Mol Life Sci 2010; 67: 701-713.
13. Neu D, Linkowski P, le Bon O. Clinical complaints of daytime sleepiness and fatigue: how to distinguish and treat them, especially when they become 'excessive' or 'chronic'? Acta Neurol Belg 2010; 110: 15-25.
14. Neu D, Mairesse O, Hoffmann G, et al. Do 'sleepy' and 'tired' go together? Rasch analysis of the relationships between sleepiness, fatigue and nonrestorative sleep complaints in a nonclinical population sample. Neuroepidemiology 2010; 35: 1-11.
15. Mellies U, Ragette R, Schwake C, et al. Sleep-disordered breathing and respiratory failure in acid maltase deficiency. Neurology 2001; 57: 1290-1295.
16. Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
17. Backhaus J, Junghanns K, Broocks A, et al. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J Psychosom Res 2002; 53: 737-740.
18. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545.
19. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-1123.
20. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.
21. Merkies IS, Schmitz PI, Van Der Meche FG, et al. Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve 2002; 25: 370-377.
22. Angelini C, Semplicini C, Ravaglia S, et al. New motor outcome function measures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy. Muscle Nerve 2012; 45: 831-834.
23. Steier J, Jolley CJ, Seymour J, et al. Screening for sleep-disordered breathing in neuromuscular disease using a questionnaire for symptoms associated with diaphragm paralysis. Eur Respir J 2011; 37: 400-405.
24. Meeuwesen L, Bensing J, van den Brink-Muinen A. Communicating fatigue in general practice and the role of gender. Patient Educ Couns 2002; 48: 233-242.
25. Lerdal A, Wahl A, Rustoen T, et al. Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. Scand J Public Health 2005; 33: 123-130.
26. Hagemans ML, Janssens AC, Winkel LP, et al. Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology 2004; 63: 1688-1692.
27. Hagemans ML, Laforet P, Hop WJ, et al. Impact of late-onset Pompe disease on participation in daily life activities: evaluation of the Rotterdam Handicap Scale. Neuromuscul Disord 2007; 17: 537-543.